BEIJING,
April 8,
2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
(Nasdaq: CASI), a Cayman incorporated biopharmaceutical company
focused on developing and commercializing innovative therapeutics
and pharmaceutical products, today reported that it has furnished a
current report on Form 6-K to disclose material development
relating to its dispute with Juventas. For details, please visit
below link:
https://www.sec.gov/Archives/edgar/data/1962738/000196273824000014/tmb-20240408x6k.htm
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical
company focused on developing and commercializing innovative
therapeutics and pharmaceutical products in China, the United
States, and throughout the world. The Company is focused on
acquiring, developing, and commercializing products that augment
its hematology oncology therapeutic focus as well as other areas of
unmet medical need. The Company intends to execute its plan to
become a leader by launching medicines in the Greater China market, leveraging the Company's
China-based regulatory and
commercial competencies and its global drug development expertise.
The Company's operations in China
are conducted through its wholly owned subsidiary, CASI
Pharmaceuticals (China) Co., Ltd.,
located in Beijing, China. More
information on CASI is available at
www.casipharmaceuticals.com.
CASI Forward-Looking Statements:
This announcement and the current report on Form
6-K contain forward-looking statements. These statements are made
under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can
be identified by terminology such as "will," "expects,"
"anticipates," "future," "intends," "plans," "believes,"
"estimates," "confident" and similar statements. Among other
things, the business outlook and quotations from management in this
announcement and the current report on Form 6-K, as well as the
Company's strategic and operational plans, contain forward-looking
statements. The Company may also make written or oral
forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission (the "SEC"), in in its annual
report to shareholders, in press releases and other written
materials and in oral statements made by its officers, directors or
employees to third parties. Statements that are not historical
facts, including statements about the Company's beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties. A number of
factors could cause actual results to differ materially from those
contained in any forward-looking statement, including but not
limited to the following: the risk that we may be unable to
continue as a going concern as a result of our inability to raise
sufficient capital for our operational needs; the possibility that
we may be delisted from trading on The Nasdaq Capital Market if we
fail to satisfy applicable continued listing standards; the
volatility in the market price of our ordinary shares; the risk of
substantial dilution of existing shareholders in future share
issuances; the difficulty of executing our business strategy on a
global basis including China; our
inability to enter into strategic partnerships for the development,
commercialization, manufacturing and distribution of our proposed
product candidates or future candidates; legal or regulatory
developments in China that
adversely affect our ability to operate in China, our lack of experience in manufacturing
products and uncertainty about our resources and capabilities to do
so on a clinical or commercial scale; risks relating to the
commercialization, if any, of our products and proposed products
(such as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks); our inability to predict when
or if our product candidates will be approved for marketing by the
U.S. Food and Drug Administration, European Medicines Agency, PRC
National Medical Products Administration, or other regulatory
authorities; our inability to enter into strategic partnerships for
the development, commercialization, manufacturing and distribution
of our proposed product candidates or future candidates; the risks
relating to the need for additional capital and the uncertainty of
securing additional funding on favorable terms; the risks
associated with our product candidates, and the risks associated
with our other early-stage products under development; the risk
that result in preclinical and clinical models are not necessarily
indicative of clinical results; uncertainties relating to
preclinical and clinical trials, including delays to the
commencement of such trials; our ability to protect our
intellectual property rights; the lack of success in the clinical
development of any of our products; and our dependence on third
parties; the risks related to our dependence on Juventas to conduct
the clinical development of CNCT19 and to partner with us to
co-market CNCT19; risks related to our dependence on Juventas to
ensure the patent protection and prosecution for CNCT19; risks
relating to the commercialization, if any, of our proposed products
(such as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks); risks relating to interests
of our largest shareholder and our Chairman and CEO that differ
from our other shareholders; and risks related to the development
of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co.,
Ltd. Further information regarding these and other risks is
included in the Company's filings with the SEC. All information
provided herein is as of the date of this announcement and the
current report on Form 6-K, and the Company undertakes no
obligation to update any forward-looking statement, except as
required under applicable law.
EVOMELA® is proprietary to
Acrotech Biopharma Inc. and its
affiliates. FOLOTYN® is proprietary
to Acrotech Biopharma Inc and its affiliates.
COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-reports-development-relating-to-its-disputes-with-juventas-302110387.html
SOURCE CASI Pharmaceuticals